Proton Radiation Therapy After Chemotherapy in the Management of Aggressive Mediastinal Non-Hodgkin Lymphomas: A Particle Therapy Cooperative Group Lymphoma Subcommittee Collaboration

Dunleavy, 2015, Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: Do they require a unique therapeutic approach?, Blood, 125, 33, 10.1182/blood-2014-05-575092 Dabrowska-Iwanicka, 2014, Primary mediastinal large B-cell lymphoma, Curr Hematol Malig Rep, 9, 273, 10.1007/s11899-014-0219-0 Vassilakopoulos, 2016, PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy, Leukemia, 30, 238, 10.1038/leu.2015.120 Rieger, 2011, Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: Results of the Mabthera International Trial Group study, Ann Oncol, 22, 664, 10.1093/annonc/mdq418 Hayden, 2020, Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: Impact of a PET-adapted approach, Blood, 136, 2803, 10.1182/blood.2019004296 Messmer, 2019, R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma, Leuk Lymphoma, 60, 1261, 10.1080/10428194.2018.1519812 Xu, 2013, Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy, Leuk Lymphoma, 54, 1684, 10.3109/10428194.2012.746684 Hoppe, 2021, Primary mediastinal B cell lymphoma in the positron-emission tomography era executive summary of the American Radium Society appropriate use criteria, Int J Radiat Oncol Biol Phys, 111, 36, 10.1016/j.ijrobp.2021.03.035 Giulino-Roth, 2017, Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R, Br J Haematol, 179, 739, 10.1111/bjh.14951 Dunleavy, 2013, Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma, N Engl J Med, 368, 1408, 10.1056/NEJMoa1214561 Melani, 2018, End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: A paradigm shift in clinical decision making, Haematologica, 103, 1337, 10.3324/haematol.2018.192492 Tseng, 2017, Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) lymphoma subcommittee, Int J Radiat Oncol, 99, 825, 10.1016/j.ijrobp.2017.05.004 Tseng, 2021, Risk of pneumonitis and outcomes after mediastinal proton therapy for relapsed/refractory lymphoma: A PTCOG and PCG collaboration, Int J Radiat Oncol Biol Phys, 109, 220, 10.1016/j.ijrobp.2020.08.055 Li, 2011, Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma, Int J Radiat Oncol Biol Phys, 81, 167, 10.1016/j.ijrobp.2010.05.007 Tian, 2018, The evolution of proton beam therapy: Current and future status, Mol Clin Oncol, 8, 15 Hoppe, 2012, Consolidative involved-node proton therapy for stage IA-IIIB mediastinal Hodgkin lymphoma: Preliminary dosimetric outcomes from a phase II study, Int J Radiat Oncol Biol Phys, 83, 260, 10.1016/j.ijrobp.2011.06.1959 Maraldo, 2013, Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma, Ann Oncol Off J Eur Soc Med Oncol, 24, 2113, 10.1093/annonc/mdt156 Tseng, 2019, Comparative photon and proton dosimetry for patients with mediastinal lymphoma in the era of Monte Carlo treatment planning and variable relative biological effectiveness, Radiat Oncol, 14, 243, 10.1186/s13014-019-1432-8 Cheson, 2014, Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification, J Clin Oncol, 32, 3059, 10.1200/JCO.2013.54.8800 Eisenhauer, 2009, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Svoboda, 2021, Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas, Haematologica, 106, 1705, 10.3324/haematol.2019.238675 Nanda, 2017, Pulmonary toxicity following proton therapy for thoracic lymphoma, Int J Radiat Oncol Biol Phys, 99, 494, 10.1016/j.ijrobp.2017.04.001 Chera, 2009, Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: Conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy, Int J Radiat Oncol Biol Phys, 75, 1173, 10.1016/j.ijrobp.2008.12.048 König, 2019, Consolidative mediastinal irradiation of malignant lymphoma using active scanning proton beams: Clinical outcome and dosimetric comparison, Strahlentherapie Onkol, 195, 677, 10.1007/s00066-019-01460-7 Sachsman, 2015, Proton therapy in the management of non-Hodgkin lymphoma, Leuk Lymphoma, 56, 2608, 10.3109/10428194.2015.1014364 Andolino, 2011, Dosimetric comparison of involved-field three-dimensional conformal photon radiotherapy and breast-sparing proton therapy for the treatment of Hodgkin's lymphoma in female pediatric patients, Int J Radiat Oncol Biol Phys, 81, e667, 10.1016/j.ijrobp.2011.01.061 Dabaja, 2018, Proton therapy for adults with mediastinal lymphomas: The International Lymphoma Radiation Oncology Group guidelines, Blood, 132, 1635, 10.1182/blood-2018-03-837633 Pedroni, 2005, Experimental characterization and physical modelling of the dose distribution of scanned proton pencil beams, Phys Med Biol, 50, 541, 10.1088/0031-9155/50/3/011 Dowdell, 2013, Interplay effects in proton scanning for lung: A 4D Monte Carlo study assessing the impact of tumor and beam delivery parameters, Phys Med Biol, 58, 4137, 10.1088/0031-9155/58/12/4137 Zeng, 2016, Proton pencil beam scanning for mediastinal lymphoma: Treatment planning and robustness assessment, Acta Oncol (Madr), 55, 1132, 10.1080/0284186X.2016.1191665 Chang, 2017, Consensus guidelines for implementing pencil-beam scanning proton therapy for thoracic malignancies on behalf of the PTCOG thoracic and lymphoma subcommittee, Int J Radiat Oncol Biol Phys, 99, 41, 10.1016/j.ijrobp.2017.05.014 Mageras, 2004, Deep inspiration breath hold and respiratory gating strategies for reducing organ motion in radiation treatment, Semin Radiat Oncol, 14, 65, 10.1053/j.semradonc.2003.10.009 Mah, 2000, Technical aspects of the deep inspiration breath-hold technique in the treatment of thoracic cancer, Int J Radiat Oncol, 48, 1175, 10.1016/S0360-3016(00)00747-1 Boda-Heggemann, 2016, Deep inspiration breath hold-based radiation therapy: A clinical review, Int J Radiat Oncol Biol Phys, 94, 478, 10.1016/j.ijrobp.2015.11.049 Moreno, 2020, Effect of deep inspiration breath hold on normal tissue sparing with intensity modulated radiation therapy versus proton therapy for mediastinal lymphoma, Adv Radiat Oncol, 5, 1255, 10.1016/j.adro.2020.08.004 Edvardsson, 2019, Comparative treatment planning study for mediastinal Hodgkin's lymphoma: Impact on normal tissue dose using deep inspiration breath hold proton and photon therapy, Acta Oncol (Madr), 58, 95, 10.1080/0284186X.2018.1512153 Hoppe, 2017, Comparing breath hold and free breathing during intensity-modulated radiation therapy and proton therapy in patients with mediastinal hodgkin lymphoma, Int J Part Ther, 3, 492, 10.14338/IJPT-17-00012 Ng, 2002, Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger, J Clin Oncol Off J Am Soc Clin Oncol, 20, 2101, 10.1200/JCO.2002.08.021 König, 2020, Secondary malignancy risk following proton vs. x-ray treatment of mediastinal malignant lymphoma: A comparative modeling study of thoracic organ-specific cancer risk, Front Oncol, 10, 989, 10.3389/fonc.2020.00989 Eaton, 2015, Secondary malignancy risk following proton radiation therapy, Front Oncol, 5, 261, 10.3389/fonc.2015.00261 Xiang, 2020, Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy, Cancer, 126, 3560, 10.1002/cncr.32938 Cwynarski, 2019, The management of primary mediastinal B-cell lymphoma: A British Society for Haematology Good Practice paper, Br J Haematol, 185, 402, 10.1111/bjh.15731 Zelenetz, 2016, Diffuse large B-cell lymphoma version 1.2016, J Natl Compr Canc Netw, 14, 196, 10.6004/jnccn.2016.0023 Taparra, 2020, Reducing heart dose with protons and cardiac substructure sparing for mediastinal lymphoma treatment, Int J Part Ther, 7, 1, 10.14338/IJPT-20-00010.1